Spinal Muscular AtrophyPhase 3SHINENCT02594124
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
A Phase 3 study testing nusinersen in people with Spinal Muscular Atrophy, run by Biogen at 47 sites in 14 countries.
Trial summary
The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Spinal Muscular Atrophy
- What is being tested?
- nusinersen
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 292 participants
- Where
- 47 sitesin 14 countries
- Study dates
- 4 Nov 2015to 21 Aug 2023
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Signed informed consent of parent or guardian and signed informed assent of participant, if indicated per participant's age and institutional guidelines.
- Completion of the index study in accordance with the study protocol or as a result of Sponsor decision (e.g., early termination of the index study) within the preceding 16 weeks
Who cannot join
- Have any condition or worsening condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study
- Clinically significant abnormalities in hematology or clinical chemistry parameters or electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit that would render the participant unsuitable for participation in the study
- Participant's parent or legal guardian is not willing or able to meet standard of care guidelines (including vaccinations and respiratory syncytial virus prophylaxis if available), nor provide nutritional and respiratory support throughout the study
- Treatment with another investigational agent, biological agent, or device within one month of Screening, or 5 half-lives of study agent, whichever is longer
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
47 sites in 14 countries.
47 sites in 14 countries
United States18 sites
Children's Hospital Colorado
Aurora, Colorado, 80045
The Johns Hopkins Hospital
Baltimore, Maryland, 21287
Boston Children's Hospital
Boston, Massachusetts, 02115
Children's Medical Center
Dallas, Texas, 75235
Duke University School of Medicine
Durham, North Carolina, 27710
Oregon Health Sciences University
Durham, Oregon, 97239
Connecticut Children's Medical Center
Hartford, Connecticut, 06106
David Geffen School of Medicine at UCLA
Los Angeles, California, 90095-8344
Duke University School of Medicine
Miyagi, North Carolina, 27710
Ann & Robert H. Lurie Children's Hospital of Chicago
New York, Illinois, 60611
Columbia University Medical Center
New York, New York, 10032
University of Utah
Obu, Aichi, Utah, 84112
Nemours Children's Clinic
Orlando, Florida, 32827
Stanford University School of Medicine
Palo Alto, California, 94305
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota, 55101
Seattle Children's Hospital
Seattle, Washington, 98105
Washington University School of Medicine
St Louis, Missouri, 63110
Japan6 sites
Kumamoto University Hospital
Kumamoto, 860-8556
Miyagi Prefectural Children Hospital
Miyagi, 989-3126
University of Miyazaki Hospital
Miyazaki, 889-1692
Hyogo College of Medicine
Nishinomiya, Hyōgo, 663-8501
Aichi Children's Health and Medical Center
Ōbu, Aichi-ken, 474-0038
Tokyo Women's Medical University
Shinjuku-ku, Tokyo, 162-8666
Canada3 sites
Children's Health Research Institute
Brussel, Ontario, N6A 5W9
McGill University Health Centre
Montreal, Quebec, H4A 3J1
BC Children's Hospital / UBC
Vancouver, British Columbia, V6H 3V4
Germany3 sites
Universitatsklinikum Essen
Essen, 45147
Universitaetsklinikum Freiburg
Freiburg im Breisgau, 79106
LMU-Campus Innenstadt
Munich, Bavaria, 80337
Italy3 sites
Pediatric Neurology Unit, Catholic University
Essen, 00168
Istituto Giannina Gaslini, Centro Traslazionale di Miologia
Genova, 16147
Department of Neuroscience, Università di Messina, AOU Polic
Messina, 98125
Spain3 sites
Hospital Sant Joan de Deu
Barcelona, 08950
Hospital Universitario Vall de Hebron
Hebron, 08035
Hospital Universitario La Paz
Madrid, 28046
Australia2 sites
Royal Children's Hospital
Parkville, Victoria, 3052
Sydney Children's Hospital Clinical Research Centre
Sydney, New South Wales, 2031
Turkey (Türkiye)2 sites
Uníversity of Hacettepe
Ankara, 6100
Marmara University Pendik Training and Research Hospital
Istanbul, 34662
United Kingdom2 sites
UCL Institute of Child Health
London, WC1N 1EH
MRC Centre for Neuromuscular Diseases at Newcastle
Newcastle, Northumberland, NE1 3BZ
Hong Kong1 site
The University of Hong Kong
Hong Kong, Hong Kong SAR, 999077
About this study
Official title: An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443
The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine the long-term efficacy of nusinersen administered by IT injection to participants with SMA who previously participated in investigational studies of nusinersen.
Read the detailed description
This study was initiated and the protocol was registered by Ionis Pharmaceuticals, Inc.
In August 2016, Biogen assumed responsibility for this study.
- Conditions
- Spinal Muscular Atrophy
- Being tested
- nusinersen
- Keywords
- SMA, SMN, SMNRx, ISIS-SMNRx, ISIS 396443, SHINE, IONIS-SMNRx, IONIS-SMN Rx, Spinraza, nusinersen
- Medical subject headings
- Muscular Atrophy, Spinal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
nusinersenDrug
Also called ISIS 396443, Spinraza, BIIB058, IONIS SMN Rx
Administered by intrathecal (IT) injection
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Experimental | Participants transitioned from ISIS 396443-CS3B (NCT02193074) Receives: Drug: nusinersen |
| Group 2 | Experimental | Participants transitioned from ISIS 396443-CS4 (NCT02292537) Receives: Drug: nusinersen |
| Group 3 | Experimental | Participants transitioned from ISIS 396443-CS12 (NCT02052791) Receives: Drug: nusinersen |
| Group 4 | Experimental | Participants transitioned from ISIS 396443-CS3A (NCT01839656) Receives: Drug: nusinersen |
| Group 5 | Experimental | Participants transitioned from 232SM202 (NCT02462759) Receives: Drug: nusinersen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE:unfavorable and unintended sign, symptom, or disease temporally associated with study/use of an investigational drug, whether or not it's considered related to investigational drug. SAE:AE that in view of either Investigator/Sponsor, meets any of the following criteria: results in death;is life-threatening:i.e.poses risk of death, hospitalization/it's prolongation;results in a persistent or significant incapacity or substantial disruption of normal life functions;results in congenital anomaly or birth defect in offspring;is an important event in the opinion of Investigator/Sponsor. TEAE: if it was present prior to first dose of nusinersen or first sham procedure in index study and subsequently worsened in severity/was not present prior to first dose of nusinersen or first sham procedure in index study but subsequently appeared.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Number of Participants With Vital Sign Abnormalities Reported as AEs
The vital sign assessments included blood pressure, temperature, pulse rate, and respiratory rate. Participants with abnormalities in these assessments recorded as AEs were reported.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Number of Participants With Weight Abnormalities Reported as AEs
Weight decrease was characterized by a decrease of >=7% from baseline and weight increase was characterized by an increase of >=7% from baseline. Participants with these abnormalities recorded as AEs were reported.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Number of Participants With Neurological Abnormalities Reported as AEs
Participants with abnormalities in neurological examinations recorded as AEs were reported.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Number of Participants With Laboratory Abnormalities Reported as AEs
Laboratory investigations included hematology, coagulation, serum chemistry and urinalysis parameters. Participants with abnormalities in these laboratory investigations recorded as AEs were reported.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Number of Participants With Coagulation Parameters Reported as AEs
Coagulation parameters included activated partial thromboplastin time (aPTT) and international normalized ratio (INR). Participants with abnormalities in these coagulation parameters recorded as AEs were reported.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Number of Participants With Clinically Significant Shifts in12 Lead Electrocardiogram (ECG) Results
Clinical significance of abnormalities in 12 lead ECG was determined based on the investigator's discretion.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Number of Participants Taking Any Concomitant Medication
A concomitant therapy is any non-protocol-specified drug or substance (including over-the-counter medications, herbal medications, and vitamin supplements) administered between the beginning of screening and the last telephone contact or study visit.
Measured: From Day 1 up to the end of the study (up to 2848 days)
Secondary outcomes (24)
Mean Number of New Motor Milestones Achieved as Assessed by World Health Organization (WHO) Criteria
The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone and walking alone. Mean of number of new milestones achieved was calculated and reported in this outcome measure.
Measured: MMDR Period: At Day 1800
Percentage of Participants With <2 Years of Age Who Attained Motor Milestones as Assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)
HINE is evaluated in infants between 2-24 months of age. It's a simple, standardized instrument including 26 items assessing different aspects of neurological examinations, such as cranial nerves, posture, movements, tone, and reflexes. In this study, Module 2 of HINE (HINE-2) was assessed, which evaluates 8 developmental milestones (head control, sitting, voluntary grasp, ability to kick, rolling, crawling, standing, and walking) scored on a 3, 4, or 5-point scale, with 0 indicating inability to perform task and score of 2, 3, or 4 indicating full milestone development. Total score is calculated by summing item scores to give maximum possible score of 26. Higher score indicates good neurological function.
Measured: At Day 309
Number of Participants Who Died or Met Permanent Ventilation
Permanent ventilation was defined as tracheostomy or >=16 hours of ventilator support per day continuously for >21 days in the absence of an acute reversible event.
Measured: MMDR Period: Up to Day 1800
Number of Participants Not Requiring Permanent Ventilation
Permanent ventilation was defined as tracheostomy or >=16 hours of ventilator support per day continuously for >21 days in the absence of an acute reversible event.
Measured: MMDR Period: Up to Day 1800
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale
The CHOP INTEND test is designed to evaluate the motor skills of infants with significant motor weakness, including infants with SMA. Participants who are ≥2 years will be continued to be assessed until a CHOP INTEND maximum score of 64 is achieved. It includes 16 items structured to move from easiest to hardest with the grading including gravity eliminated (lower scores) to antigravity movements (higher scores). All item scores range from 0 (worst) to 4 (best). Total scores range from 0 to 64, with higher scores indicating better movement functioning.
Measured: Baseline, Day 2198
Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score
The HFMSE consists of 33 scored activities used to assess motor function in children with SMA. Participants were asked to do a specific activity (such as rolling) and they were then graded on the quality and execution of that movement on a scale of 0=being unable, 1=performed with some compensation, and 2=unaided. The overall score is the sum of the scores for all activities with a maximum achievable score of 66. Higher scores indicate increased motor function.
Measured: MMDR Period: Baseline, MMDR Day 1800
Change From Baseline in Revised Upper Limb Module (RULM) Total Score
RULM Test is used in participants with SMA to assess upper limb functional ability items and has total of 20 items with an entry item that serves as functional class identification and does not contribute to total score. Remaining 19 scorable items reflect different functional domains and graded on 3-point system with score of 0 (unable), 1 (able, with modification), and 2 (able, no difficulty). There is only 1 item that is scored as a can/cannot score, with 1 as the highest score. Scorable items are summed for total score (0-37), higher scores indicating increased upper limb function. Positive change from baseline indicates improvement.
Measured: MMDR Period: Baseline, MMDR Day 1800
Change From Baseline in Total Distance Walked Over Time as Assessed by 6-Minute Walk Test (6MWT)
The 6MWT measures the distance an individual can walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Measured: Baseline, Day 2670
Number of Participants Who Experienced Contracture Assesment
Contracture assessment is performed to assess the motor performance in SMA. The number of participants who experienced at least one contracture at any location and severe contractures in any of the five locations (hip flexors, knee flexors, ankle planter flexors, elbow flexors, forearm flexors) are reported in this outcome measure.
Measured: MMDR Period: At MMDR Day 1800
Change From Baseline in Compound Muscular Action Potential (CMAP)
CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles. Peroneal amplitude (PA) and ulnar amplitude (UA) data is reported in this OM. Score <0 indicated worse response and >0 indicated better response than the normal matched population. Score change <0 indicated worsening and >0 indicated improvement as compared to baseline.
Measured: MMDR Period: Baseline, MMDR Day 1800
Change From Baseline in Body Length
Participants were analyzed for change in growth parameter of body length to evaluate clinical efficacy. The body length was calculated using either WHO or Centers for Disease Control and Prevention (CDC) scales. The CDC scale allows to calculate the body length up to 20 years, while the WHO scale allows to calculate it only up to 10 years.
Measured: MMDR Period: up to Day 1800
Change From Baseline in Weight
Participants were analyzed for change in growth parameter of weight to evaluate clinical efficacy. The weight was calculated using either WHO or CDC scales. The CDC scale allows to calculate the weight up to 20 years, while the WHO scale allows to calculate it only up to 10 years.
Measured: MMDR Period: up to Day 1800
Change From Baseline in Weight for Age Percentile
Participants who were below the age of 36 months were analyzed for change in growth parameter of weight for age to evaluate clinical efficacy. The weight for age percentile was calculated using either WHO or CDC scales. The CDC scale allows to calculate the weight for age percentile up to 20 years, while the WHO scale allows to calculate it only up to 10 years.
Measured: MMDR Period: up to Day 1800
Percentage of CMAP Responders
CMAP is an electrophysiological technique that can be used to determine the approximate number of motor neurons in a muscle or group of muscles. A participant was defined as a responder if they had a peroneal amplitude ≥1 mV at last visit (including the amplitude ≥1 mV at baseline and also demonstrated as such at last visit).
Measured: MMDR Period: At Day 1800
Number of Participants Who Achieved Motor Milestones
Motor milestones were measured based on WHO criteria. The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: sitting without support (SWS), standing with assistance (SWA), hands and knees crawling (HKC), and walking alone (WA).
Measured: MMDR Period: up to Day 1800
Number of Participants Who Achieved Standing Alone and Walking With Assistance
Motor milestones were measured based on WHO criteria. The WHO motor milestones are a set of six milestones in motor development, all of which would be expected to be attained by 24 months of age in healthy children. The individual milestones are: SWS, SWA, HKC, WWA, WA and standing alone (SA). SA and WWA were assessed in this outcome measure.
Measured: MMDR Period: up to Day 1800
Total Number of Hospitalizations Due to Serious Respiratory Events
Total number of hospitalizations is total number of serious events that occurred during study for all participants under each group. For a participant with multiple SAEs which started at the same date and led to hospitalization, it is counted as one hospitalization.
Measured: Up to day 2520
Total Number of Hospitalizations Due to Serious Adverse Events
Total number of hospitalizations is total number of serious events that occurred during study for all participants under each group. For a participant with multiple SAEs which started at the same date and led to hospitalization, it is counted as one hospitalization.
Measured: Up to day 2520
Percent of Time in Hospitalization
Measured: Upto day 2160
Change From Baseline in Cobb-Angle on X-Ray of the Thoracolumbar Spine by Visit
Cobb angle is a measurement of the degree of side-to-side spinal curvature used to define scoliosis.
Measured: MMDR Period: Baseline, MMDR Day 1800
Pediatric Quality of Life Inventory (PedsQL) Questionnaires Total Score by Domain
Items on the PedsQL generic core scale are reverse scored and transformed to a 0-100 scale. The PedsQL parent (P) and self (S) reported questionnaire was collected for participants from 2 to 25 years of age. Four dimensions were collected: Physical, Emotional, Social and School functioning and each item was scored on a 5 point ordinal scale. 0 (never) =100, 1 (almost never) = 75, 2 (sometimes)= 50, 3 (often) = 25, 4 (almost always) = 0. A total score was calculated as the sum of all the items over the number of items answered on all the scales. If more than 50% of items or more were missing, the scale score was not computed. Higher scores indicated better health related quality of life.
Measured: MMDR Period: At Day 1800
Change From Baseline in Assessment of Caregiver Experience With Neuromuscular Disease (ACEND) Questionnaire Total Score
The ACEND is a questionnaire that includes a total of seven domains assessing physical impact (including feeding/grooming/dressing, sitting/play, transfers, and mobility) and general caregiver impact (including time, emotion, and finance) and each domain comprises several items. The total score (TS) for each domain will be calculated on a scale of 0 to 100. Higher scores indicate a greater impact on the caregiver.
Measured: MMDR Period: up to Day 1800
Number of Participants With Disease-related Hospitalizations and AEs
Measured: MMDR Period: up to Day 1800
Survival Rate
Survival rate was defined as the percentage of participants alive during the study and was estimated from the Kaplan Meier (KM) curve for time to death.
Measured: MMDR Period: up to Day 1800
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2015 (estimated)
- Study start4 Nov 2015
- Primary completion21 Aug 2023
- Study completion21 Aug 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Spinal Muscular AtrophyStudies of the same condition, open and under way.
- More trials run by BiogenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 292 participants (actual)
Sponsor and investigators
- Lead sponsor
- Biogen
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Biogen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02594124
- Sponsor's protocol ID
- ISIS 396443-CS11
- Other IDs
- 2015-001870-16, 2015
- Acronym
- SHINE
- Status last verified
- Sep 2024
- First submitted
- 30 Oct 2015
- Last updated
- 22 Oct 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Expanded access
- Available
Publications
Kokaliaris C, Evans R, Hawkins N, Mahajan A, Scott DA, Sutherland CS, Nam J, Sajeev G. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy. Adv Ther. 2024 Jun;41(6):2414-2434. doi: 10.1007/s12325-024-02845-6. Epub 2024 May 5.
PubMed 38705943
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443
- ClinicalTrials.gov ID
- NCT02594124
- Acronym / sponsor ID
- SHINE / ISIS 396443-CS11
- Conditions
- Spinal Muscular Atrophy
- Keywords
- SMA, SMN, SMNRx, ISIS-SMNRx, ISIS 396443, SHINE, IONIS-SMNRx, IONIS-SMN Rx
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 292 participants (actual)
- Lead sponsor
- BiogenIndustry (pharma, biotech, devices)
- Study start
- 4 Nov 2015 (actual)
- Primary completion
- 21 Aug 2023 (actual)
- Study completion
- 21 Aug 2023 (actual)
- First posted
- 2 Nov 2015 (estimated)
- Results
- Posted 22 Oct 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine the long-term efficacy of nusinersen administered by IT injection to participants with SMA who previously participated in investigational studies of nusinersen.
Detailed description
This study was initiated and the protocol was registered by Ionis Pharmaceuticals, Inc.
In August 2016, Biogen assumed responsibility for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Experimental | Drug: nusinersenParticipants transitioned from ISIS 396443-CS3B (NCT02193074) |
| Group 2 | Experimental | Drug: nusinersenParticipants transitioned from ISIS 396443-CS4 (NCT02292537) |
| Group 3 | Experimental | Drug: nusinersenParticipants transitioned from ISIS 396443-CS12 (NCT02052791) |
| Group 4 | Experimental | Drug: nusinersenParticipants transitioned from ISIS 396443-CS3A (NCT01839656) |
| Group 5 | Experimental | Drug: nusinersenParticipants transitioned from 232SM202 (NCT02462759) |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Signed informed consent of parent or guardian and signed informed assent of participant, if indicated per participant's age and institutional guidelines.
- Completion of the index study in accordance with the study protocol or as a result of Sponsor decision (e.g., early termination of the index study) within the preceding 16 weeks
Key exclusion criteria (5 listed)
- Have any condition or worsening condition which in the opinion of the Investigator would make the participant unsuitable for enrollment, or could interfere with the participant participating in or completing the study
- Clinically significant abnormalities in hematology or clinical chemistry parameters or electrocardiogram (ECG), as assessed by the Site Investigator, at the Screening visit that would render the participant unsuitable for participation in the study
- Participant's parent or legal guardian is not willing or able to meet standard of care guidelines (including vaccinations and respiratory syncytial virus prophylaxis if available), nor provide nutritional and respiratory support throughout the study
- Treatment with another investigational agent, biological agent, or device within one month of Screening, or 5 half-lives of study agent, whichever is longer
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| nusinersenAlso: ISIS 396443, Spinraza, BIIB058, IONIS SMN RxAdministered by intrathecal (IT) injection | Drug | Group 1, Group 2, Group 3, Group 4, Group 5 |
Primary outcome
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to the end of the study (up to 2848 days)
AE:unfavorable and unintended sign, symptom, or disease temporally associated with study/use of an investigational drug, whether or not it's considered related to investigational drug. SAE:AE that in view of either Investigator/Sponsor, meets any of the following criteria: results in death;is life-threatening:i.e.poses risk of death, hospitalization/it's prolongation;results in a persistent or significant incapacity or substantial disruption of normal life functions;results in congenital anomaly or birth defect in offspring;is an important event in the opinion of Investigator/Sponsor. TEAE: if it was present prior to first dose of nusinersen or first sham procedure in index study and subsequently worsened in severity/was not present prior to first dose of nusinersen or first sham procedure in index study but subsequently appeared.
Number of Participants With Vital Sign Abnormalities Reported as AEs
Time frame: From Day 1 up to the end of the study (up to 2848 days)
The vital sign assessments included blood pressure, temperature, pulse rate, and respiratory rate. Participants with abnormalities in these assessments recorded as AEs were reported.
Number of Participants With Weight Abnormalities Reported as AEs
Time frame: From Day 1 up to the end of the study (up to 2848 days)
Weight decrease was characterized by a decrease of >=7% from baseline and weight increase was characterized by an increase of >=7% from baseline. Participants with these abnormalities recorded as AEs were reported.
Number of Participants With Neurological Abnormalities Reported as AEs
Time frame: From Day 1 up to the end of the study (up to 2848 days)
Participants with abnormalities in neurological examinations recorded as AEs were reported.
Number of Participants With Laboratory Abnormalities Reported as AEs
Time frame: From Day 1 up to the end of the study (up to 2848 days)
Laboratory investigations included hematology, coagulation, serum chemistry and urinalysis parameters. Participants with abnormalities in these laboratory investigations recorded as AEs were reported.
Number of Participants With Coagulation Parameters Reported as AEs
Time frame: From Day 1 up to the end of the study (up to 2848 days)
Coagulation parameters included activated partial thromboplastin time (aPTT) and international normalized ratio (INR). Participants with abnormalities in these coagulation parameters recorded as AEs were reported.
Number of Participants With Clinically Significant Shifts in12 Lead Electrocardiogram (ECG) Results
Time frame: From Day 1 up to the end of the study (up to 2848 days)
Clinical significance of abnormalities in 12 lead ECG was determined based on the investigator's discretion.
Number of Participants Taking Any Concomitant Medication
Time frame: From Day 1 up to the end of the study (up to 2848 days)
A concomitant therapy is any non-protocol-specified drug or substance (including over-the-counter medications, herbal medications, and vitamin supplements) administered between the beginning of screening and the last telephone contact or study visit.
24 secondary outcomes
Mean Number of New Motor Milestones Achieved as Assessed by World Health Organization (WHO) Criteria
Time frame: MMDR Period: At Day 1800
Percentage of Participants With <2 Years of Age Who Attained Motor Milestones as Assessed by Section 2 of Hammersmith Infant Neurological Examination (HINE)
Time frame: At Day 309
Number of Participants Who Died or Met Permanent Ventilation
Time frame: MMDR Period: Up to Day 1800
Number of Participants Not Requiring Permanent Ventilation
Time frame: MMDR Period: Up to Day 1800
Change From Baseline in Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale
Time frame: Baseline, Day 2198
Change From Baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) Total Score
Time frame: MMDR Period: Baseline, MMDR Day 1800
Change From Baseline in Revised Upper Limb Module (RULM) Total Score
Time frame: MMDR Period: Baseline, MMDR Day 1800
Change From Baseline in Total Distance Walked Over Time as Assessed by 6-Minute Walk Test (6MWT)
Time frame: Baseline, Day 2670
Number of Participants Who Experienced Contracture Assesment
Time frame: MMDR Period: At MMDR Day 1800
Change From Baseline in Compound Muscular Action Potential (CMAP)
Time frame: MMDR Period: Baseline, MMDR Day 1800
Change From Baseline in Body Length
Time frame: MMDR Period: up to Day 1800
Change From Baseline in Weight
Time frame: MMDR Period: up to Day 1800
Change From Baseline in Weight for Age Percentile
Time frame: MMDR Period: up to Day 1800
Percentage of CMAP Responders
Time frame: MMDR Period: At Day 1800
Number of Participants Who Achieved Motor Milestones
Time frame: MMDR Period: up to Day 1800
Number of Participants Who Achieved Standing Alone and Walking With Assistance
Time frame: MMDR Period: up to Day 1800
Total Number of Hospitalizations Due to Serious Respiratory Events
Time frame: Up to day 2520
Total Number of Hospitalizations Due to Serious Adverse Events
Time frame: Up to day 2520
Percent of Time in Hospitalization
Time frame: Upto day 2160
Change From Baseline in Cobb-Angle on X-Ray of the Thoracolumbar Spine by Visit
Time frame: MMDR Period: Baseline, MMDR Day 1800
Pediatric Quality of Life Inventory (PedsQL) Questionnaires Total Score by Domain
Time frame: MMDR Period: At Day 1800
Change From Baseline in Assessment of Caregiver Experience With Neuromuscular Disease (ACEND) Questionnaire Total Score
Time frame: MMDR Period: up to Day 1800
Number of Participants With Disease-related Hospitalizations and AEs
Time frame: MMDR Period: up to Day 1800
Survival Rate
Time frame: MMDR Period: up to Day 1800
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38705943Kokaliaris C, Evans R, Hawkins N, Mahajan A, Scott DA, Sutherland CS, Nam J, Sajeev G. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy. Adv Ther. 2024 Jun;41(6):2414-2434. doi: 10.1007/s12325-024-02845-6. Epub 2024 May 5.
- Cure SMALink provided by the sponsor.
- Muscular Dystrophy AssociationLink provided by the sponsor.
- National Organization for Rare DiseasesLink provided by the sponsor.
Related trials for Spinal Muscular Atrophy
Active, not recruitingObservational study
A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
Muscular Atrophy, Spinal
Recruiting
Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
Cerebral Palsy, Muscular Dystrophy
Recruiting
SMAdult - Monitoring of Movement on Spinal Muscular Atrophy
Spinal Amyotrophy
Active, not recruitingPhase 1
A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec
Healthy Volunteer, Muscular Atrophy, Spinal
Recruiting
Effects of Different Stiffness Settings During Robotic Isokinetic Training in Children With SMA
Spinal Muscular Atrophy (SMA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Director study director
Biogen
47 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing nusinersen in people with Spinal Muscular Atrophy, run by Biogen at 47 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 47 sites in United States, Japan, Canada, Germany, Italy and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Oct 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) (time frame: From Day 1 up to the end of the study (up to 2848 days)). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02594124, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2024.